At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 12 enrolled
Drug / intervention
Trametinib 0.5 mg +5 moredrug
Likely dose
Trametinib 0.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1 Trial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung Cancer
In Brief
A Phase 2 clinical trial evaluating Trametinib 0.5 mg, Trametinib 1 MG, and 4 other interventions for Non Small Cell Lung Cancer and KRAS Gene Mutation. Completed, enrolled 12 participants across 7 sites.
Detailed Summary
The purpose of this study is to evaluate the safety of the combination of ponatinib and trametinib as well as the most appropriate dosages of the combination.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon Small Cell Lung Cancer, KRAS Gene Mutation
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
Enrollment StartOct 2018
First PostedOct 2018
Primary CompletionFeb 2022
TodayJul 2026
First PostedOct 15, 2018
Enrollment StartOct 9, 2018
Primary CompletionFeb 4, 2022
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 7.7 years ago
Interventions
Trametinib 0.5 mgdrug
0.5mg PO q daily
Trametinib 1 MGdrug
1.0 mg PO q daily
Trametinib 1.5 MGdrug
1.5mg PO q daily
Trametinib 2 mgdrug
2 mg PO q daily
Ponatinib 15 MGdrug
15mg PO q daily
Ponatinib 30 MGdrug
30mg PO q daily